Current status and perspectives of cell therapy in Chagas disease
AUTOR(ES)
Soares, Milena Botelho Pereira, Santos, Ricardo Ribeiro dos
FONTE
Memórias do Instituto Oswaldo Cruz
DATA DE PUBLICAÇÃO
2009-07
RESUMO
One century after its discovery, Chagas disease, caused by the protozoan, Trypanosoma cruzi, remains a major health problem in Latin America. Mortality and morbidity are mainly due to chronic processes that lead to dysfunction of the cardiac and digestive systems. About one third of the chronic chagasic individuals have or will develop the symptomatic forms of the disease, with cardiomyopathy being the most common chronic form. This is a progressively debilitating disease for which there are no currently available effective treatments other than heart transplantation. Like in other cardiac diseases, tissue engineering and cell therapy have been investigated in the past few years as a means of recovering the heart function lost as a consequence of chronic damage caused by the immune-mediated pathogenic mechanisms elicited in individuals with chronic chagasic cardiomyopathy. Here we review the studies of cell therapy in animal models and patients with chronic Chagas disease and the perspectives of the recovery of the heart function lost due to infection with T. cruzi.
Documentos Relacionados
- Current situation and perspectives regarding human Chagas disease in midwestern of the state of Minas Gerais, Brazil
- Perspectives of vaccination in Chagas disease revisited
- Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
- Challenges and perspectives of Chagas disease: a review
- Elimination of Chagas disease transmission: perspectives